Twist Bioscience Corp
For the period ended Dec 31, 2025. Filed Feb 2, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 2, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited)
| Three months ended December 31, | ||
|---|---|---|
| (In thousands, except per share data) | 2025 | 2024 |
| Revenues [1] | $103,698 | $88,713 |
| Costs and expenses: | ||
| Cost of revenues | $49,726 | $45,873 |
| Research and development expenses | 17,130 | 21,307 |
| Selling, general and administrative expenses[2] | 69,742 | 56,177 |
| Total costs and expenses | $136,598 | $123,357 |
| Loss from operations | $(32,900) | $(34,644) |
| Interest income | 2,175 | 3,240 |
| Other income (expense), net [3] | 471 | (93) |
| Loss before income taxes | $(30,254) | $(31,497) |
| Income tax expense | (253) | (97) |
| Net loss | $(30,507) | $(31,594) |
| Other comprehensive loss: | ||
| Change in unrealized gain (loss) on investments | $18 | $(66) |
| Foreign currency translation adjustment | 38 | (61) |
| Comprehensive loss | $(30,451) | $(31,721) |
| Net loss per share — basic and diluted | $(0.50) | $(0.53) |
| Weighted average shares used in computing net loss per share — basic and diluted | 61,080 | 59,162 |
[1] Including revenues from related parties of $1.4 million and $4.0 million during the three months ended December 31, 2025 and December 31, 2024, respectively
[2]Including variable sublease income from a related party of $0.2 million and $— million for the three months ended December 31, 2025 and December 31, 2024, respectively.
[3]Including sublease income from a related party of $0.5 million and $— million for the three months ended December 31, 2025 and December 31, 2024, respectively
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.